Sol-Gel Technologies (SLGL) Stock Forecast & Price Target

Sol-Gel Technologies is attractive because SGT-610 targets Gorlin syndrome, a severe, underserved condition where patients can develop dozens or even hundreds of BCCs and face repeated painful surgeries, creating a compelling unmet need for a topical, well-tolerated therapy. The company’s recent KOL event reinforced that thousands of diagnosed U.S. patients may be receptive to treatment, while the pivotal Phase 3 is already fully enrolled with 113 patients, 102 completers, and top-line data expected late next month, giving investors a near-term catalyst. Financially, the stock screens modestly valued versus upside from a potential first-in-class product, with end-1Q26 cash and marketable securities of about $52.8M, a March 2026 offering raising $33.1M, and additional franchise support from TWYNEO and EPSOLAY partnerships that could generate up to $4.5M in milestones and roughly $10M in annual royalties by 2031.

Sol-Gel Technologies is facing a highly challenged outlook because SGT-610 is essentially a redo of PellePharm’s failed Phase 3, which missed statistical significance in 2021 and was acquired for only about $5M upfront in 2023, underscoring limited prior confidence. The current trial’s reliance on a retrospective subgroup signal raises replication risk, while the highly variable endpoint of new facial BCCs over 12 months makes another miss or a weak effect plausible even after enrichment efforts. Even if approval is achieved, commercial success remains uncertain because reimbursement is not assured and a smaller-than-expected benefit could limit physician adoption and reduce the product’s value proposition.